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Peduction in Ventricular Tachyarrhythmias
ith Statins in the Multicenter Automatic
efibrillator Implantation Trial (MADIT)-II
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rian Olshansky, MD,§ Scott A. McNitt, MS,* W. Jackson Hall, PHD,† Wojciech Zareba, MD, PHD,*
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ADIT-II Research Group
ochester and New York, New York; St. Louis Park, Minnesota; Iowa City, Iowa; and Boston, Massachusetts
OBJECTIVES We evaluated whether statins have anti-arrhythmic effects by exploring the association of
statin use with appropriate implantable cardioverter-defibrillator (ICD) therapy for ventric-
ular tachycardia/ventricular fibrillation (VT/VF) in the Multicenter Automatic Defibrillator
Implantation Trial (MADIT)-II.
BACKGROUND A few studies have suggested that lipid-lowering drugs may have anti-arrhythmic effects in
patients with coronary artery disease.
METHODS Patients receiving an ICD (n  654; U.S. centers only) in the MADIT-II study were
categorized by the percentage of days each patient received statins during follow-up (90% to
100%, n 386; 11% to 89%, n 116; and 0% to 10%, n 152). The Kaplan-Meier method
with significance testing by the log-rank statistic and time-dependent proportional hazards
regression analysis were used to evaluate the effect of statin use on the probability of ICD
therapy for the combined end point VT/VF or cardiac death and for the end point VT/VF.
RESULTS The cumulative rate of ICD therapy for VT/VF or cardiac death, whichever occurred first,
was significantly reduced in those with 90% statin usage compared to those with lower
statin usage (p  0.01). The time-dependent statin:no statin therapy hazard ratio was 0.65
(p 0.01) for the end point of VT/VF or cardiac death and 0.72 (p 0.046) for VT/VF after
adjusting for relevant covariates.
CONCLUSIONS Statin use in patients with an ICD was associated with a reduction in the risk of cardiac death
or VT/VF, whichever occurred first, and was associated with a reduction in VT/VF episodes.
These findings suggest that statins have anti-arrhythmic properties. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.0532006;47:769–73) © 2006 by the American College of Cardiology Foundation
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pudden cardiac death (SCD) accounts for more than 50% of
he deaths due to heart disease (1), with the vast majority
rom ventricular tachyarrhythmias. Statin-type hypolipi-
emic drugs have been shown to reduce mortality and
ardiac death in patients with coronary artery disease
CAD) (2,3). These drugs also reduce the incidence of first
cute major coronary events in subjects without overt CAD
ho have average levels of total cholesterol and low-density
ipoprotein cholesterol (4). Recent data suggest that lipid-
owering drugs may have anti-arrhythmic effects (5,6).
The Multicenter Automatic Defibrillator Implantation
rial (MADIT)-II database includes information regarding
entricular arrhythmia (VA) occurrence obtained from ICD
nterrogation as well as detailed drug information during
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f Physicians and Surgeons, New York, New York; and the ¶Cardiology Division of
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ity, Boston, Massachusetts. The MADIT-II study was supported by a research grant
rom Guidant Corp., St. Paul, Minnesota, to the University of Rochester School of
edicine and Dentistry.c
Manuscript received May 13, 2005; revised manuscript received September 4, 2005,
ccepted September 26, 2005.ollow-up (7,8). The purpose of this study was to investigate
hether statin use is associated with reduced VAs in
atients receiving an ICD in the MADIT-II study.
ETHODS
tudy subjects. The design, inclusion and exclusion crite-
ia, and primary results of the MADIT-II study have been
reviously described (7,8). Briefly, 1,232 patients who were
21 years old, had a myocardial infarction one month or
ore before entry, and an ejection fraction 0.30 were
andomized to ICD implant plus conventional medical
herapy or conventional medical therapy alone in a 3:2 ratio.
Of 742 patients randomized to defibrillator therapy, 720
ctually received an ICD. The study population consisted of 654
CD-treated patients in whom detailed information of drug
herapy for every day in the trial was available. Lipid-lowering
herapy (drug and dose) was prescribed at the discretion of the
reating physician. The statins used were atorvastatin, simvastatin,
ravastatin, lovastatin, cerivastatin, and fluvastatin.
ollow-up. During the three-month follow-up visits, the
ates of initiation and cessation of medications were re-
orded and ICD devices were interrogated. The average
atient follow-up was 17 months. The distribution of the
ercent of statin use during follow-up (Fig. 1) was highly
oncentrated at both ends of the range. Thus, the cut points
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Statins in the MADIT-II Study February 21, 2006:769–73f 90% and 10% statin use were arbitrarily selected, and
hree groups of patients were identified: 1) patients who
sed statins for90%of the time (n 386); 2) patients who used
tatins 11% to 89% of the time (n  116); and 3) patients who
sed statins10% of the time (n 152). As there were six statins
sed in this trial at varying dosages, no attempt was made to
ompare one statin and/or one dose to another.
nd points of the study. The prespecified primary end point
n this substudy was the first occurrence of cardiac death or
ppropriate ICD therapy (anti-tachycardia pacing or shock) for
entricular tachycardia (VT)/ventricular fibrillation (VF). The
econdary end point was first appropriate ICD therapy for
T/VF, with censoring of death when it occurred. Tertiary end
oints included sudden and non-sudden cardiac death.
A core lab reviewed all stored electrocardiograms and deter-
ined the frequency of appropriate ICD therapy for treatment of
T or VF on the basis of the interrogation findings.Details of the
CD devices, their programming, and their interrogation were
ecently reported (9). An end point committee reviewed all
ortality events, as recently reported (10).
tatistical methods. The effect of statins on the cumulative
robabilities of the end points were determined by the
aplan-Meier method, with significance testing by the
og-rank statistic. Proportional hazards regression analysis
as used to evaluate the effect of statin use (yes/no) on the
robability of ICD therapy for the combined end point
T/VF or cardiac death and for the end point VT/VF (11).
igure 1. Frequency distribution of the percentage of days during
Abbreviations and Acronyms
CAD  coronary artery disease
CI  confidence interval
ICD  implantable cardioverter-defibrillator
MADIT  Multicenter Automatic Defibrillator
Implantation Trial
SCD  sudden cardiac death
VA  ventricular arrhythmias
VF  ventricular fibrillation
VT  ventricular tachycardiat
ollow-up on which the implantable cardioverter-defibrillator treated
atients (n  654) received statin drugs.ubsequently, a time-dependent proportional hazards anal-
sis was used to evaluate the effect of statin use on these end
oints in a more precise manner. Statin use was treated as a
ime-dependent covariate, an approach that takes into
ccount each day a patient was on or off a statin during the
tudy, with the onset or offset of statin use on the day of
hange. The baseline variables that had differences between
he three statin use groups (Table 1), using a p value 0.10,
nd variables that were thought to be of clinical relevance,
ere evaluated in the proportional hazards stepwise selec-
able 1. Baseline Clinical Characteristics of Patients by Use of
tatins During Follow-up*
Variable
<10%
Statin Use
(n  152)
11%–89%
Statin Use
(n  116)
>90%
Statin Use
(n  386)
p
Value
ge 65 yrs 68 48 50 0.01
en 82 81 85 0.47
on-Hispanic whites 82 84 89 0.12
ast treatment for
hypertension
55 57 51 0.43
ast treatment for
ventricular
arrhythmias
10 14 10 0.57
urrent or former
cigarette smoker
78 80 81 0.63
iabetes mellitus 30 41 33 0.14
YHA functional class
II–IV†
72 66 62 0.10
lood urea nitrogen
25 mg/dl
40 36 24 0.01
oronary angioplasty 38 42 50 0.03
oronary artery bypass
graft
54 59 61 0.28
nterval of 18 months
between most recent
MI and enrollment
73 74 79 0.37
eart rate 80 beats/min 35 37 27 0.07
ual chamber ICD 45 38 50 0.06
ardiac findings at
enrollment
Atrial fibrillation 11 13 7 0.12
QRS interval 0.12 s 43 43 38 0.45
Left bundle branch
block
19 21 18 0.68
Right bundle branch
block
9 10 9 0.94
Ejection fraction 0.25 54 57 45 0.04
edications at enrollment
Beta-blockers 50 68 67 0.01
Calcium antagonists 13 10 13 0.72
Digitalis 66 64 58 0.14
ACE inhibitors 78 75 78 0.82
Amiodarone 7 9 6 0.41
Class I anti-arrhythmics 3 3 2 0.67
Diuretics 82 77 71 0.03
alues are expressed as percentages. The p values are for a comparison of the three
roups by a chi-square test or a Fisher’s exact test. *Statin use (10%, 11% to 89%,
90%) reflects the percentage of days the patients received statins during follow-up.
ee Methods for further details. †New York Heart Association (NYHA) functional
lass recorded in the 3-month period before enrollment.
ACE  angiotensin-converting enzyme; ICD  implantable cardioverter-
efibrillator.ion model. Only covariates with a p value 0.05 in the
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February 21, 2006:769–73 Statins in the MADIT-II Studyroportional-hazards model were included in the final
odel. All tests of statistical significance were two-sided.
AS version 9.1.3 (SAS Institute, Cary, North Carolina)
as used in the data analyses.
ESULTS
aseline characteristics. Of the 720 patients in the ICD
rm, 67% were taking lipid-lowering drugs (statins in
6%) at baseline, and of the 490 patients in the conven-
ional therapy arm, 65% were taking lipid-lowering drugs
statins in 96%) at baseline. The baseline characteristics of
he patients grouped by statin use (10%, 11% to 89%,
90% of the follow-up time in the trial) are presented in
able 1. The group receiving statins for 90% of the
ollow-up time were younger and had lower blood urea
itrogen, less diuretic use, more coronary angioplasty,
igher ejection fraction and greater beta-blocker use com-
igure 2. (A) Cumulative probability of appropriate implantable cardiov
entricular fibrillation (VT/VF) by percentage of days that statin therapy wa
raph are the number of patients at risk in the time period; the p value assess
CD therapy for VT/VF by percentage of days that statin therapy was used (90
re the number of patients at risk in the time period; the p value assesses differared with the group receiving statins 10% of the
ollow-up time (p  0.05).
tatin effects on VT/VF. The cumulative probabilities of
ime to appropriate therapy for the combined end point
T/VF or cardiac death and for just VT/VF by statin usage
re presented in Figures 2A and 2B, respectively. When
omparing the 90% statin versus the 10% statin use
roups, there was a lower cumulative probability of VT/VF
r cardiac death (p  0.01) and of VT/VF (p  0.06).
tatin use was associated with a significant reduction in SCD
p  0.01), but no meaningful reduction in non-sudden
ardiac death (p 0.21) in the 90% statin group compared
ith the 10% statin group (Figs. 3A and 3B).
Time-dependent statin use, using a time delay of zero
ays, was associated with a hazard ratio of 0.65 (95%
onfidence interval [CI] 0.49 to 0.87; p  0.01) for the
ombined end point cardiac death (n  42) or appropriate
defibrillator (ICD) therapy for cardiac death or ventricular tachycardia/
(90%, 11% to 89%, and10%) during follow-up. Numbers below each
ferences among the three curves. (B) Cumulative probability of appropriateerter-
s used
es dif%, 11% to 89%, and 10%) during follow-up. Numbers below each graph
ences among the three curves.
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Statins in the MADIT-II Study February 21, 2006:769–73T/VF therapy (n  153), whichever comes first, and 0.72
95% CI 0.52 to 0.99; p  0.046) for the single end point
ppropriate VT/VF therapy, after adjusting for relevant
ovariates, which were beta-blocker use, blood urea nitrogen
25 mg/dl, and New York Heart Association functional
lass 2 (Table 2). These hazard ratios translate into risk
eductions of 35% for cardiac death or VT/VF and 28% for
T/VF, respectively.
Time-dependent statin use, using a time delay of four
eeks, was associated with adjusted hazard ratios of 0.77
95% CI 0.58 to 1.04; p  0.08) and 0.79 (95% CI 0.57 to
.11; p  0.17) for the two specified end points, respectively.
ISCUSSION
he principal finding of this analysis is that statin use was
ssociated with fewer VT/VF episodes. There was a 28%
igure 3. (A) Cumulative probability of death classified as sudden cardiac
10%) during follow-up. Numbers below each graph are the number of pa
urves. (B) Cumulative probability of death classified as non-sudden cardia
10%) during follow-up. Numbers below each graph are the number of pa
urves.eduction in the risk of a first VT/VF episode with statin use. cThis study adds to the findings from several other studies.
e Sutter et al. (5) examined 78 patients with coronary
isease and life-threatening VA treated with ICD therapy.
atients who received lipid-lowering therapy had fewer VA
pisodes compared with those who did not (6 of 27 or 22%,
s. 29 of 51 or 57%, p  0.05). Mitchell et al. (6) examined
A recurrence rates in patients who had CAD and near-
atal VA and received an ICD. There was a 40% reduction
n the risk of VA recurrence in the group that received
ipid-lowering therapy (n 83; 79% statins) compared with
he group that did not (n  279) (reduction in hazard 0.40,
5% CI 0.15 to 0.58), after adjusting for baseline inequities.
hiu et al. (12) studied 281 patients who had CAD and
nderwent ICD implantation and observed a reduction in
rst ICD therapy for VA (adjusted hazard ratio 0.60, p 
.01) among patients who used statin therapy (n  154)
ercentage of days that statin therapy was used (90%, 11% to 89%, and
at risk in the time period; the p value assesses differences among the three
percentage of days that statin therapy was used (90%, 11% to 89%, and
at risk in the time period; the p value assesses differences among the three, by p
tients
c, byompared with those who did not (n  127).
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February 21, 2006:769–73 Statins in the MADIT-II StudyStatins have also been reported to improve regulation of
oronary arterial tone and nitric oxide-mediated endothelial
unction, inhibit cell proliferation, stabilize atherosclerotic
laques, have anti-inflammatory properties, and provide
nti-oxidant effects. The mechanism by which statins re-
uce VAs may relate indirectly to one or more of these
ffects. For example, the anti-oxidant and anti– cell-
roliferative effects of statins may play a role in plaque
tabilization and thus contribute to an anti-arrhythmic effect
y reducing ischemia-related ventricular tachyarrhythmias.
f interest, statin therapy has been associated with im-
roved survival in heart failure patients independent of its
ffect on cholesterol levels (13).
Dietary polyunsaturated fatty acids have been reported
o favorably alter the structure of the phospholipid part of
he cardiac cell membrane and provide immediate anti-
rrhythmic effects in lab experiments (14–16). We speculate
hat statins may similarly alter the lipid portions of the
embrane through which the transmembrane segments
f ion channels penetrate, thereby affecting ion-channel
onductances. Statins may also have some membrane-
tabilizing properties. The exact mechanism by which
tatins may reduce arrhythmias is unknown.
Several lines of evidence from our study favor the hypoth-
sis that statins have anti-arrhythmic properties. First, a
ose-response effect was present. Second, the time-
ependent analysis revealed a greater decrease in VA in
atients taking statin therapy compared with those not
aking a statin, using a time delay of zero days rather than
our weeks. This suggests an immediate effect of these drugs
ather than a delayed effect related to a slowing of the rate
f progression of atherosclerosis. Third, the findings have
iologic plausibility related to potential lipid-altering effects
n the cardiac cell membrane.
tudy limitations. This was an observational study and statin
able 2. Effect of Statin Therapy on Cardiac Death and ICD
herapy for Ventricular Tachyarrhythmias
Cardiac Death or ICD
Therapy for VT/VF
Hazard Ratio† (95% CI)
ICD Therapy for VT/VF
Hazard Ratio† (95% CI)
tatin* 0.65 (0.49, 0.87) 0.72 (0.52, 0.99)
Value 0.004 0.046
Time-dependent statin use, using a time-delay of zero days (see Methods). The
ariables evaluated in the proportional hazards regression stepwise selection model
ere age 65 yrs, congestive heart failure New York Heart Association (NYHA)
unction class2, blood urea nitrogen (BUN)25 mg/dl, coronary angioplasty, heart
ate 80 beats/min, dual chamber implantable cardioverter-defibrillator (ICD),
jection fraction (EF) 0.25, beta-blocker use, diuretic use, coronary artery bypass
raft, atrial fibrillation, and QRS duration 0.12 s. †This hazard ratio is adjusted for
UN 25 mg/dl, congestive heart failure NYHA functional class 2, and beta-
locker use, the only three variables that made a significant contribution to the
ombined end point model. There were eight missing observations in this model due
o missing information about BUN in one patient and NYHA functional class in
even patients. Analyses are based on 153 ventricular tachycardia/ventricular fibrilla-
ion (VT/VF) events and 42 cardiac death events not preceded by VT/VF events.herapy was not randomized. The higher statin-use subjectsay have been less sick than the lower statin-use subjects,
nd there may have been incomplete statistical adjustment
or observed imbalances. In addition, there may be imbal-
nce in other relevant variables that were not measured.
onclusions. In the MADIT-II study, statins were asso-
iated with a reduced risk of cardiac death or VT/VF and
ith reduced VT/VF episodes. These findings suggest that
tatins have anti-arrhythmic properties.
eprint requests and correspondence: Dr. Anant K. Vyas, Heart
esearch Follow-up Program, University of Rochester Medical
enter, 601 Elmwood Avenue, Box 653, Rochester, New York
4642. E-mail: anantvyas@hotmail.com.
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